Mineralys Therapeutics Files Q3 2024 10-Q
Ticker: MLYS · Form: 10-Q · Filed: Nov 12, 2024 · CIK: 1933414
Sentiment: neutral
Topics: 10-Q, quarterly-report, pharmaceuticals
TL;DR
Mineralys Therapeutics filed its Q3 2024 10-Q. Check financials.
AI Summary
Mineralys Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company, incorporated in Delaware, operates in the Pharmaceutical Preparations sector. Its principal business address is in Radnor, Pennsylvania. The filing covers the third quarter of 2024.
Why It Matters
This filing provides investors and stakeholders with the latest financial and operational details for Mineralys Therapeutics, Inc. as of the end of the third quarter of 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Mineralys Therapeutics is subject to inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 2024 Q3 — Reporting Period (The filing covers the third quarter of 2024.)
- 2024-09-30 — Period End Date (The financial information is as of this date.)
- 2024-11-12 — Filing Date (The date the 10-Q was officially filed with the SEC.)
Key Players & Entities
- Mineralys Therapeutics, Inc. (company) — Filer of the 10-Q
- 20240930 (date) — End of the reporting period
- Radnor, Pennsylvania (location) — Company's business address
- 2834 (industry_code) — Standard Industrial Classification for Pharmaceutical Preparations
- 001-41614 (sec_file_number) — SEC file number for Mineralys Therapeutics
FAQ
What is the primary business of Mineralys Therapeutics, Inc.?
Mineralys Therapeutics, Inc. operates in the Pharmaceutical Preparations sector, as indicated by its SIC code 2834.
What is the reporting period for this 10-Q filing?
The reporting period for this 10-Q filing is the third quarter of 2024, ending on September 30, 2024.
Where is Mineralys Therapeutics, Inc. located?
The company's business and mailing address is located at 150 N. Radnor Chester Road, Suite F200, Radnor, Pennsylvania, 19087.
What is the SEC file number for Mineralys Therapeutics, Inc.?
The SEC file number for Mineralys Therapeutics, Inc. is 001-41614.
When was this 10-Q filing submitted to the SEC?
This 10-Q filing was submitted to the SEC on November 12, 2024.
Filing Stats: 4,624 words · 18 min read · ~15 pages · Grade level 16 · Accepted 2024-11-12 08:36:36
Key Financial Figures
- $0.0001 — nge on which registered Common stock, $0.0001 par value per share MLYS The Nasdaq S
Filing Documents
- mlys-20240930.htm (10-Q) — 720KB
- mlys3q2410qex311.htm (EX-31.1) — 10KB
- mlys3q2410qex312.htm (EX-31.2) — 10KB
- mlys3q2410qex321.htm (EX-32.1) — 5KB
- mlys3q2410qex322.htm (EX-32.2) — 5KB
- 0001933414-24-000057.txt ( ) — 3799KB
- mlys-20240930.xsd (EX-101.SCH) — 28KB
- mlys-20240930_cal.xml (EX-101.CAL) — 34KB
- mlys-20240930_def.xml (EX-101.DEF) — 113KB
- mlys-20240930_lab.xml (EX-101.LAB) — 389KB
- mlys-20240930_pre.xml (EX-101.PRE) — 268KB
- mlys-20240930_htm.xml (XML) — 352KB
- Financial Information
Part I - Financial Information 1
Financial Statements
Item 1. Financial Statements 1
Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 16
Quantitative and Qualitative Disclosures About Market Risk
Item 3. Quantitative and Qualitative Disclosures About Market Risk 28
Controls and Procedures
Item 4. Controls and Procedures 29
- Other Information
Part II - Other Information 30
Legal Proceedings
Item 1. Legal Proceedings 30
Risk Factors
Item 1A. Risk Factors 30
Unregistered Sales of Equity Securities and Use of Proceeds
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 30
Defaults Upon Senior Securities
Item 3. Defaults Upon Senior Securities 30
Mine Safety Disclosures
Item 4. Mine Safety Disclosures 30
Other Information
Item 5. Other Information 30
Exhibits
Item 6. Exhibits 30 i Table of Contents
- Financial Information
Part I - Financial Information
Financial Statements
Item 1. Financial Statements Mineralys Therapeutics, Inc. Condensed Balance Sheets (in thousands, except share and per share amounts) September 30, December 31, 2024 2023 (unaudited) Assets Current assets: Cash and cash equivalents $ 97,274 $ 49,304 Investments 166,329 187,263 Prepaid and other current assets 4,129 12,536 Total current assets 267,732 249,103 Investments, noncurrent — 2,482 Property and equipment, net 69 — Other assets 452 51 Total assets $ 268,253 $ 251,636 Liabilities and stockholders' equity Current liabilities: Accounts payable $ 3,106 $ 601 Accrued liabilities 28,215 9,881 Total current liabilities 31,321 10,482 Commitments and contingencies (Note 4) Stockholders' equity: Common stock, $ 0.0001 par value; 500,000,000 shares authorized as of September 30, 2024 and December 31, 2023; 49,755,946 and 41,133,916 shares issued and outstanding as of September 30, 2024 and December 31, 2023, respectively 5 4 Additional paid-in capital 490,499 365,858 Accumulated deficit ( 253,572 ) ( 124,708 ) Total stockholders' equity 236,932 241,154 Total liabilities and stockholders' equity $ 268,253 $ 251,636 The accompanying notes are an integral part of these condensed financial statements. 1 Table of Contents Mineralys Therapeutics, Inc. Condensed Statements of Operations (in thousands, except share and per share data) (unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2024 2023 2024 2023 Operating expenses: Research and development $ 53,985 $ 22,499 $ 124,012 $ 46,676 General and administrative 6,121 3,774 16,624 10,270 Total operating expenses 60,106 26,273 140,636 56,946 Loss from operations ( 60,106 ) ( 26,273 ) ( 140,636 ) ( 56,946 ) Interest income, net 3,774 3,513 11,779 9,435 Other income (expense) ( 10 ) — ( 7 ) 2 Total other income, net 3,764 3,513 11,772 9,437 Net loss $ ( 56,342 ) $ ( 22,760 ) $ ( 128,864 ) $ ( 47,509 ) Net loss per share attributable to common stoc